Hepatic involvement in congenital acute megakaryoblastic leukemia: A case report with emphasis on the liver pathology findings
Department of Pathology, Mount Sinai School of Medicine, New York, NY, USA.Pediatric and Developmental Pathology (Impact Factor: 0.87). 01/2006; 11(1):55-8. DOI: 10.2350/07-03-0243.1
We report the case of a 4-week-old infant diagnosed with acute megakaryoblastic leukemia with the t (1;22) (p13, q13) who presented with ascites caused by massive infiltration of hepatic sinusoids by leukemic cells. The bone marrow by microscopy and flow cytometry and the peripheral blood smear did not initially show the presence of blasts. Marrow fibrosis appeared after infiltrative disease in the liver and liver fibrosis. We describe the microscopic liver findings and associated clinical presentation that, in the absence of bone marrow involvement, can be difficult to diagnose as leukemia. Few cases have been reported in the medical literature with the liver as the primary site of involvement in congenital leukemia. Awareness of this unusual clinical presentation and of the characteristic liver pathology may facilitate the pathologic diagnosis.
[Show abstract] [Hide abstract]
- "The median age of presentation is 6 years, ranging from 3 months to 16 years, but cases (40%) have been seen in children of age 41 months or younger. The youngest reported case of AML-M7 reported earlier was a 4-week-old neonate who presented with hepatic infiltration only. "
ABSTRACT: Congenital leukemia (CL) is an extremely rare disorder in the newborn, significant proportion of which is of myeloid origin, primarily of M4 or M5 morphology. As compared to pediatric leukemia, CL is a more aggressive disease. Acute myeloid leukemia (AML-M7) or acute megakaryocytic leukemia is a rare type of AML with an incidence of 0.5 per million per year. Median age of presentation is 6 years, and children may present with a broad variety of symptoms including low-grade fever, diarrhea, easy bruising, failure to gain weight and life-threatening conditions.Indian journal of medical and paediatric oncology 07/2011; 32(3):165-7. DOI:10.4103/0971-5851.92821
Conference Paper: MCM-D implementation of passive RF components: Chip/package tradeoffs[Show abstract] [Hide abstract]
ABSTRACT: MCM-D technology offers the capability to integrate passive components with ICs. Currently, most application volume is in a frequency range between 800 MHz and 2 GHz. On-chip integration of inductors in this range poses particular problems because of the conflicting needs for small size and high quality factor. MCM technology offers a way to tightly integrate inductors and capacitors in a more cost-effective fashion. To use this approach to its best advantage requires closely coupled design of ICs and substrate and calls for new design methodologies that can work across different technologiesIC/Package Design Integration, 1998. Proceedings. 1998 IEEE Symposium on; 03/1998
- [Show abstract] [Hide abstract]
ABSTRACT: Congenital leukemias are a rare group of hematologic neoplasms with a wide range of clinical signs and symptoms. Here we reported a neonate presenting with jaundice, pleural effusion and ascites. The total protein and serum albumin were markedly low at 48 and 12 g/L. Computerized tomography showed the density of liver was asymmetry with several hypoechoic regions. Initial blood routine examination revealed only thrombocytopenia while blood white cells increased to 30.0×10(9)/L with 17% blast cells several days later. Bone marrow biopsy showed the proportion of blasts and promonocytes increased and she was diagnosed as acute monoblastic leukemia.Fetal and pediatric pathology 01/2011; 30(1):27-31. DOI:10.3109/15513815.2010.494701 · 0.48 Impact Factor
Data provided are for informational purposes only. Although carefully collected, accuracy cannot be guaranteed. The impact factor represents a rough estimation of the journal's impact factor and does not reflect the actual current impact factor. Publisher conditions are provided by RoMEO. Differing provisions from the publisher's actual policy or licence agreement may be applicable.